Predictors of Time to Viremia With an Analytic Treatment Interruption

HIV Clinical Trial

Official title:

Predictors of Time to Viremia With an Analytic Treatment Interruption

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03033017
• Other study ID #: 24777
• Status: Withdrawn
• Phase: N/A
• First received: October 7, 2016
• Last updated: December 1, 2017
• Start date: July 2016
• Est. completion date: January 2019

Study information

• Verified date: December 2017
• Source: University of Minnesota - Clinical and Translational Science Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a two-center study of 30 HIV-infected participants who have been on antiretroviral therapy (ART) for at least two years.

Participants will be asked to undergo LN and GALT biopsies both before and after a closely monitored analytic treatment interruption (ATI).

Description:

The HIV field has made a dramatic shift to an emphasis on finding a cure for HIV.

However, there is no agreed upon test of cure, or even what the definition of a cure might be. The investigator believes the most reliable test of cure will be an analytic treatment interruption (ATI) with time to viremia as a standard measure of the impact of an intervention on the degree to which the reservoir has been depleted. This is rational as modeling studies utilizing ATI data point to reservoir size as an important predictor of time to viremia(1) and other studies have shown that levels of HIV DNA(2) and cell associated HIV RNA(3) prior to starting antiretroviral therapy (ART) are associated with time-to-rebound. However, these studies used a limited sampling strategy to determine when viremia rebounded and it is likely that greater sensitivity in measures of time-to rebound will be needed to accurately assess the impact of an intervention. The investigators have tested an ATI strategy where plasma HIV is sampled three times each week and ART is resumed once the virus becomes detectable. In this small, pilot study, the investigators sampled lymph nodes, GALT, plasma, and PBMC before, during, and after the ATI and found the time-to-rebound was 14 days (range 5 to 30 days) and that total years of ART exposure was associated with the time-to-rebound (4). The investigators propose a similar study that includes more intensive blood and lymphoid tissue sampling to identify factors that predict time to-rebound to provide a necessary foundation for future studies that utilize a treatment interruption as a test of efficacy for curative interventions.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: January 2019
• Est. primary completion date: January 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

1. HIV-infected individuals who have been on ART therapy for at least two years

2. Male or Female, aged 18 years or older

3. Documented evidence of CD4+ T cell count = 300 cells/µl for 12 months prior to study entry

4. BMI = 30 or evidence by ultrasound or physical exam of peripheral inguinal lymph node(s) that is/are surgically accessible

5. Documented plasma HIV RNA levels below level of quantification <20 to <40 copies RNA/mL depending on the assay) = 24 months (a single measurement above the level of detection but < 200 copies/ml will be allowed)

6. Willing to switch to an ART regimen consisting of dolutegravir and either tenofovir/emtricitabine or abacavir/lamivudine to avoid drugs with a long-half life that would expose the participant to a period of mono-therapy when the drugs are stopped.

7. Women of child bearing potential and men with partners of child bearing potential must agree to use effective contraception during protocol

8. Able to provide voluntary written consent.

Exclusion Criteria

1. ART was initiated during acute infection (within first 6 months of infection)

2. Planning or current pregnancy or breastfeeding

3. History and/or presence of any clinically significant disease or disorder, such as cardiovascular, pulmonary, renal, hepatic, neurological, gastrointestinal and psychiatric/mental disease/disorder, which, in the opinion of the enrolling physician, may put the participant at risk because of participation in the study, influence the results of the study, or affect the participant's ability to participate in the study.

4. Inability to comply with study procedures per enrolling physician discretion.

Related Conditions & MeSH terms

• HIV
• Viremia

Intervention

Other:
• Blood Testing

Locations

Country	Name	City	State
United States	University of Minnesota	Minneapolis	Minnesota
United States	University of California	San Francisco	California

Sponsors (1)

Lead Sponsor	Collaborator
University of Minnesota - Clinical and Translational Science Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to viremia	Time to viremia	Baseline to 14 days
Primary	Change in vRNA+ and vDNA+ cells	measured by in situ hybridization and using quantitative image analysis to determine the frequency of + cell/gram lymphoid tissue	Baseline to 14 days
Primary	SCA (Single Copy Assay)	performed as described in the protocol and reported as number of cells/ml plasma.	Baseline to 14 days
Primary	Change in markers of immune activation	All measurements are the same IL1B, TNF, IL4, IL13, IL17, IL21,IL22, IL6, IL10	Baseline to 14 days
Primary	Change in CD4		Baseline to 14 days
Primary	Change in CD4/CD8 ratio		Baseline to 14 days
Primary	Polyadenylation-RT-ddPCR assay for total transcripts (TAR)	transcripts/million cells	Baseline to 14 days
Primary	ddPCR assays for read-through, elongated, polyadenylated, and multiply-spliced (Tat-Rev) transcripts	reported as transcripts/million cells	Baseline to 14 days